Prospective Clinical Validation Studies

GEP Test: Validated by Multiple Prospective Studies

The DecisionDx-UM gene expression profile (GEP) test is a robust multianalyte assay that accurately predicts which patients are at high and low risk of developing metastatic disease within five years.  The test, along with specimen collection techniques, has been validated on both fresh-frozen samples obtained from fine-needle aspirate biopsy procedures (FNAB), and on archival tissue derived from formalin-fixed, paraffin-embedded (FFPE) samples.

Clinically, the test has completed validation and is no longer considered experimental or investigational. Seven validation and performance studies have been conducted to confirm the clinical accuracy of DecisionDx-UM and include multiple independent, retrospective, and prospective sample sets. 

Summary of Clinical Validity and Performance Studies With Reported Outcomes

Study Design n 3-year MFS or DSS 5-year MFS or DSS
Class 1A Class 1B Class 2 Class 1A Class 1B Class 2
Onken et al., 2012 Prospective
446 98% 93% 50% 98% 79% 28%
Chappell et al., 2012 Retrospective
187 93% 38%
Correa & Augsburger, 2014 Prospective
159 92% 55%
Correa & Augsburger, 2016 Prospective
299 95% 69% 92% 55%
Plasseraud et al., 2016 Prospective
70 100% 63% Reported in Aaberg et al., 2020
Demirci et al., 2018 Retrospective
293 99% 90% 60% Accrual ongoing
Aaberg et al., 2020 Prospective,
89 94% 63%
Binkley et al., 2020 Retrospective, 2-center 215 96% 63% 96% 49%

MFS, Metastasis Free Survival; DSS, Disease Specific Survival

Study Highlight: COOG Study Finds DecisionDx-UM Robust and Highly Accurate

The first prospective validation study of DecisionDx-UM was a 5-year prospective, multicenter, 494-patient study by the Collaborative Ocular Oncology Group (COOG), published in Ophthalmology (Onken et al, 2012). This study compared DecisionDx-UM to all clinical and pathologic prognostic factors and found it to be superior to, and independent of, all such factors (eg, tumor diameter, tumor thickness, patient age, histopathology involvement, cytopathology, and chromosome 3 status).

Consistent with prior retrospective and prospective single-center studies, the COOG study found the DecisionDx-UM test to be accurate in differentiating between low-risk (Class 1) tumors and high-risk (Class 2) tumors (log-rank test, p<10e-4). The Kaplan Meier plot below shows the percent of Class 1 and Class 2 patients who remained metastasis-free over 50 months of follow-up.  Additional data from this study, including multivariate analyses, can be found in Comparison to Other Prognostic Markers.

Metastasis-Free Survival (Onken et al, 2012)


Order DecisionDx®-UM

For Information

Call: 866-788-9007

What's Next?

Comparison to Other Prognostic Markers

How Do You Get a
DecisionDx-UM Test?

Scroll to Top